BRAF and melanoma: The Sal/4E1RCat combination had a minimal effect on the normal non-cancerous FF2441 fibroblast cell line (Figure 1A), but statistically significantly decreased viability in melanoma cell lines containing mutant BRAF V600E and those lacking the mutant BRAF protein (Figures 1B,C).